兴奋剂
增食欲素
受体
嗜睡症
化学
敌手
G蛋白偶联受体
小分子
药理学
神经科学
医学
神经肽
生物
生物化学
莫达非尼
作者
Chuan Hong,Noel J. Byrne,Beata Zamlynny,Srivanya Tummala,Li Xiao,Jennifer M. Shipman,Andrea T. Partridge,Christina Minnick,Michael J. Breslin,Michael T. Rudd,Shawn J. Stachel,Vanessa L. Rada,Jeffrey C. Kern,Kira A. Armacost,Scott A. Hollingsworth,Julie A. O’Brien,Dawn L. Hall,Terrence P. McDonald,Corey Strickland,Alexei Brooun
标识
DOI:10.1038/s41467-021-21087-6
摘要
Abstract Narcolepsy type 1 (NT1) is a chronic neurological disorder that impairs the brain’s ability to control sleep-wake cycles. Current therapies are limited to the management of symptoms with modest effectiveness and substantial adverse effects. Agonists of the orexin receptor 2 (OX2R) have shown promise as novel therapeutics that directly target the pathophysiology of the disease. However, identification of drug-like OX2R agonists has proven difficult. Here we report cryo-electron microscopy structures of active-state OX2R bound to an endogenous peptide agonist and a small-molecule agonist. The extended carboxy-terminal segment of the peptide reaches into the core of OX2R to stabilize an active conformation, while the small-molecule agonist binds deep inside the orthosteric pocket, making similar key interactions. Comparison with antagonist-bound OX2R suggests a molecular mechanism that rationalizes both receptor activation and inhibition. Our results enable structure-based discovery of therapeutic orexin agonists for the treatment of NT1 and other hypersomnia disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI